Review of medicinal cannabis for anxiety finds CBD has anxiolytic evidence while THC effects are mixed
Clinical trials show CBD has anxiolytic effects, but evidence is not yet strong enough for first-line treatment, while THC-containing products show mixed results and may worsen anxiety in some people.
Quick Facts
What This Study Found
CBD demonstrated anxiolytic effects in trials with healthy volunteers and clinical populations, though evidence remains insufficient for first-line treatment. THC-dominant products showed ambiguous results, with some individuals experiencing relief and others worsening anxiety. About 17% of anxiety prescriptions were for CBD-dominant products while 50% were for herbal cannabis for vaporization.
Key Numbers
17% of anxiety prescriptions for CBD-dominant products (oils, wafers, capsules); 33% for THC-containing liquids; 50% for herbal cannabis for vaporization. Anxiety is the second most common reason for medicinal cannabis prescription in Australia.
How They Did This
Review article summarizing clinical trials, laboratory studies, and prescribing data on medicinal cannabis for anxiety disorders in Australia.
Why This Research Matters
Anxiety is the second most common reason for medicinal cannabis prescriptions in Australia, yet the evidence base is still developing, creating a gap between prescribing practice and scientific certainty.
The Bigger Picture
The disconnect between rapidly increasing prescriptions and limited clinical evidence highlights a broader tension in medicinal cannabis: patient demand and practitioner willingness are outpacing the evidence from controlled trials.
What This Study Doesn't Tell Us
Review article, not a systematic review. Australian prescribing data may not reflect patterns elsewhere. The evidence base for CBD in anxiety is still mostly from small trials. No long-term outcome data reviewed.
Questions This Raises
- ?Why are THC-containing products prescribed more often than CBD for anxiety, given the stronger anxiolytic evidence for CBD?
- ?What outcomes are patients experiencing with these prescriptions?
Trust & Context
- Key Stat:
- Anxiety is #2 reason for medicinal cannabis Rx in Australia
- Evidence Grade:
- Review synthesizes existing clinical trial evidence, which includes RCTs for CBD but remains limited overall.
- Study Age:
- Published in 2022.
- Original Title:
- Medicinal cannabis for the treatment of anxiety disorders.
- Published In:
- Australian journal of general practice, 51(8), 586-592 (2022)
- Authors:
- Berger, Maximus(3), Amminger, G Paul(4), McGregor, Iain S(55)
- Database ID:
- RTHC-03705
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Is CBD or THC better for anxiety?
Based on current evidence, CBD has more consistent anxiolytic effects across trials. THC results are mixed, with some people reporting relief and others experiencing worsened anxiety. CBD also lacks the intoxicating effects and driving impairment associated with THC.
What types of cannabis products are most commonly prescribed for anxiety in Australia?
Herbal cannabis for vaporization accounts for 50% of anxiety prescriptions, THC-containing liquid products 33%, and CBD-dominant products (oils, wafers, capsules) only 17%.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-03705APA
Berger, Maximus; Amminger, G Paul; McGregor, Iain S. (2022). Medicinal cannabis for the treatment of anxiety disorders.. Australian journal of general practice, 51(8), 586-592. https://doi.org/10.31128/AJGP-04-21-5936
MLA
Berger, Maximus, et al. "Medicinal cannabis for the treatment of anxiety disorders.." Australian journal of general practice, 2022. https://doi.org/10.31128/AJGP-04-21-5936
RethinkTHC
RethinkTHC Research Database. "Medicinal cannabis for the treatment of anxiety disorders." RTHC-03705. Retrieved from https://rethinkthc.com/research/berger-2022-medicinal-cannabis-for-the
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.